SGLT2 inhibitors also attenuate mRNA and protein level expression of inflammatory markers including NLRP3, IL-1β, and tumor necrosis factor-α in kidney and myocardium of a diabetic mouse model, and retard the progression of diabetic kidney disease and cardiomyopathy29,30. Here, SLC5A2 is linked to diabetes mellitus.